Charged Alpha Stock Encyclopedia

Tesla, Inc. (TSLA) Q2 2026 — Tesla (TSLA) reported a record-but-hollow Q2 2026: revenue of $28.24B (+26% YoY) beat the ~$26.4B estimate and pushed trailing revenue past $100B for the first time ever, on a Q2-record 480,126 deliveries (+25%) and record 13.5 GWh of energy storage (+41%). But profit collapsed: GAAP operating income fell 57% to $398M — a 1.4% margin, down from 4.1% a year ago — and non-GAAP EPS of $0.33 missed the ~$0.51 consensus (-18% YoY). Automotive gross margin was 16.9% (just 16.3% ex regulatory credits); total gross margin slipped to 16.8%. Operating expenses jumped 47% to $4.35B on AI, Optimus and robotaxi spend plus CEO-package stock comp; capex more than doubled to $5.79B; and free cash flow turned negative at -$1.09B, Tesla's first cash burn since early 2024. Regulatory credits collapsed 67% to $146M and, with the EV tax credit and CAFE penalties gone, aren't coming back. GAAP net income of $1.11B (-5%) leaned on a $590M Bitcoin/FX gain in other income. The balance sheet is a fortress ($43.5B cash & investments, ~$34B net of debt). Yet at a ~$1.4T market cap, our sum-of-the-parts values the visible business (cars + energy + services + net cash) at only ~$70/share — meaning ~$300/share (>80% of the market cap) is pure autonomy optionality. Our call: HOLD, 2/5, fair value ~$260 vs a ~$374 price.

Tesla is the most valuable and most argued-about car company on Earth — worth about $1.4 trillion — and Q2 2026 was a study in contradiction. On top, everything was a record: revenue of $28.24B (+26% YoY, beating ~$26.4B), a Q2-record 480,126 deliveries, record 13.5 GWh of energy storage (+41%), and the first-ever $100B trailing-twelve-month revenue. But almost none of it reached the bottom line. GAAP operating income collapsed 57% to $398M — a 1.4% operating margin — and adjusted EPS of $0.33 badly missed the ~$0.51 the Street wanted (-18% YoY). Why? Lower average selling prices (volume, not pricing power), a 47% surge in operating expenses to $4.35B on AI compute, Optimus and robotaxi plus Musk's pay-package stock comp, and a 67% collapse in regulatory credits to $146M (a near-pure-profit crutch that policy just killed for good). Capex more than doubled to $5.79B, pushing free cash flow to -$1.09B — Tesla's first cash burn since early 2024 — and automotive gross margin ex-credits was just 16.3%. Reported net income of $1.11B (-5%) only held up thanks to a $590M Bitcoin and currency gain. The balance sheet remains a fortress ($43.5B cash, ~$34B net). So the debate isn't the vision — it's the price. On our sum-of-the-parts, the whole visible business (cars + energy + services + net cash) is worth only ~$70/share; the other ~$300 (over $1 trillion, >80% of the market cap) is what the market pays purely for autonomy — robotaxi (now live in 7 US metros), FSD (1.48M subscriptions), and Optimus (not yet in volume production). Probability-weighting a bear ($90), base ($260) and bull ($530) scenario, our fair value lands near $260 — about 30% below the ~$374 price. Our call: HOLD, 2/5 — an extraordinary company with a fortress balance sheet and a genuinely thrilling future, but priced for an autonomy win it has not yet shipped. We're more cautious than the Street's deeply split ~$420 average target (range $125-$600). Own the vision if you believe it; just don't confuse it with a margin of safety. Not financial advice.

THE CALL: HOLD (2/5, PRICED FOR AUTONOMY IT HASN'T SHIPPED — RECORD REVENUE, A 1.4% OPERATING MARGIN, AND OVER $1 TRILLION OF THE MARKET CAP RIDING ON A FUTURE NOT YET SHIPPED) — base-case value ~$260 vs ~$374 today.

What to watch: hard proof the autonomy moonshots are real — unsupervised robotaxi scaling profitably well beyond a handful of metros, Optimus reaching volume production, and automotive gross margins recovering — which would justify the optionality premium and could prompt an upgrade; the risks to respect are robotaxi and Optimus timelines slipping (staying perpetually ~18 months away), intensifying EV competition and pricing pressure, and the now-structural loss of high-margin regulatory-credit revenue, any of which could re-rate a stock still priced for perfection at ~$1.4 trillion

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Texas Instruments (TXN) Q2 2026 — Texas Instruments (TXN), the world's largest maker of analog chips, reported a clean beat-and-raise for Q2 2026: GAAP EPS of $2.14 topped the ~$1.91 estimate (+52% YoY) on revenue of $5.46B (+23% YoY), gross margin expanded to 61.4% (+347 bps) and operating profit jumped 48% to $2.31B (42% margin). Analog grew 26% to $4.37B (46% operating margin) and Embedded Processing rose 16%. A broad cyclical upturn drove it: industrial +30%, data center roughly doubled, auto inflected on China EV demand. Trailing free cash flow surged 271% to $6.5B (34% of sales) as the 300mm fab capex wave rolled off to a $2-3B/yr pace. Management guided Q3 revenue to $5.65-6.15B and EPS to $2.23-2.57, above the Street. Yet the stock — up ~90% off its $153 low to ~$294, near its $332 record — slipped after the print. The catch: at ~34x forward earnings and a 2.4% FCF yield, even our optimistic compounder DCF lands near $235. Our call: HOLD.

Texas Instruments is the bluest of blue-chip chipmakers — the world's #1 maker of analog and embedded chips, the humble, high-margin silicon inside almost every electronic device. Q2 2026 was a genuinely strong quarter: GAAP EPS of $2.14 beat the ~$1.91 estimate (+52% YoY), revenue rose 23% to $5.46B, gross margin expanded to 61.4% (+347 bps) and operating profit surged 48% to $2.31B (a 42% margin). The driver was a broad cyclical upturn — industrial +30% YoY, data center roughly doubled, and automotive inflected higher led by China EV demand — after two years of brutal downturn. The number bulls love: trailing free cash flow up 271% to $6.5B (34% of sales), as TI's multi-year 300mm fab capex wave rolls off to just $2-3B/yr (last quarter capex fell below depreciation). Management guided Q3 revenue to $5.65-6.15B and EPS to $2.23-2.57, above the Street. So the debate isn't quality — it's price. The stock has run ~90% off its $153 low to ~$294, near its $332 record, and actually slipped after this clean beat. At ~34x forward earnings and a 2.4% FCF yield, TI is priced for perfection — and part of the FCF surge is CHIPS Act cash (~$1.6B TTM), not pure earnings power. Even leaning to the optimistic compounder path (11% FCF growth) with a premium 9% discount rate, our owner-earnings DCF lands fair value near $235 — about 20% below the price. Our call: HOLD, 3/5. A world-class franchise with no margin of safety, and we're more cautious than the Street's ~$298 average target (which itself implies just +1% upside). Add on real weakness toward the low $200s. Not financial advice.

THE CALL: HOLD (3/5, A GREAT FRANCHISE AT A FULL PRICE — A CLEAN BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$235 vs ~$294 today.

What to watch: evidence this is a long, secular up-cycle rather than an ordinary one — broadening industrial and automotive content growth, TI's new price increases sticking, and free cash flow marching toward management's $8-9/share framework — which would justify the premium multiple and prompt an upgrade; the risk to respect is the semiconductor cycle rolling back over (orders cooling, inventories rebuilding, China softening), which at ~34x forward earnings and a 2.4% FCF yield could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Dr. Reddy's Laboratories Ltd. (RDY) Q1 FY2027 — Dr. Reddy's (RDY), the ~$9.5B Indian generics-and-specialty pharma, reported Q1 FY2027 (quarter ended June 30) on July 22 — and the NYSE ADR fell ~9.4% to a fresh 52-week low. Net profit collapsed 69% to ₹443 crore (~$46M) and revenue slipped 6% to ₹80.7B (~$837M), missing estimates by nearly half; EBITDA fell 56% and the margin more than halved, from 26.7% to 12.5%. But two very different things caused it: a KNOWN patent cliff — the four-year generic-Revlimid (lenalidomide) window closed in January, sending North America down 35% — and a ONE-TIME ₹240-crore semaglutide API write-off. Strip both out and the base business grew double-digits everywhere else: Emerging Markets +31%, India +17%, Europe +13%, PSAI +4%. Dr. Reddy's runs a net-cash balance sheet (₹3,058 cr surplus, ~$317M) and reaffirmed FY27 guidance. Diluted EPS fell from ₹17.00 to ₹5.30 (~$0.055/ADR). Our owner-earnings DCF centers near $10 vs the ~$11.40 price.

Dr. Reddy's Laboratories (RDY) is one of India's largest drugmakers — a ~$9.5B generics-and-specialty pharma in Hyderabad, run by G V Prasad and CEO Erez Israeli, that sells complex generics mostly into the U.S. On July 22 it reported a Q1 FY2027 that looked catastrophic: net profit down 69% to ₹443 crore, revenue down 6% to ₹80.7B, EBITDA down 56%, diluted EPS from ₹17.00 to ₹5.30 — and the ADR fell ~9% to a 52-week low. But the collapse was mostly two one-off items. First, a KNOWN cliff: a four-year limited-competition license to sell generic Revlimid (lenalidomide) — a high-margin windfall — expired in January, driving North America down 35% to ₹2,205 crore. Second, a genuine ONE-TIME stumble: a ₹240-crore write-off of an out-of-spec semaglutide API batch (supply expected back by late Oct/early Nov). Strip both out and the underlying base grew double-digits in every other region — Emerging Markets +31%, India +17%, Europe +13% — and the adjusted EBITDA margin was 15.4%. The balance sheet is net cash (₹3,058 cr surplus), R&D runs ~7% of sales, and management reaffirmed FY27 guidance. The bull case: over-punished for a known cliff plus a one-timer. The bear case: the U.S. profit windfall is structurally gone, the semaglutide slip flags execution risk on the very pivot (peptides/biosimilars) meant to replace it, and on normalized earnings the stock isn't cheap. Our owner-earnings DCF (base ~$420M FCF, +5%/+10% paths, 8.5–11.5% discount for EM + FX risk, ADD net cash, ~834M shares) centers near $10 vs ~$11.40 — the ~9% drop closed the gap but left no margin of safety. Our call: HOLD, 3/5. We're MORE CAUTIOUS than the Street (lean Buy, ~$14.5 ADR target, ~+27% — but those targets predate the miss). We'd buy under ~$9, or on proof the refill is working. Not financial advice.

THE CALL: HOLD (3/5, A NET-CASH PHARMA IN A SELF-INFLICTED TROUGH — A KNOWN LENALIDOMIDE CLIFF PLUS A ONE-TIME SEMAGLUTIDE STUMBLE, BUT WITH THE U.S. WINDFALL GONE AND THE REFILL UNPROVEN, THE ~9% DROP LEFT NO MARGIN OF SAFETY) — base-case value ~$10 vs ~$11.40 today.

KEY METRICS:

- Revenue ₹80.7B (~$837M), −6% YoY — missed ~₹88B estimate

- Net profit ₹443 cr (~$46M), −69% YoY — missed ~₹818 cr estimate by nearly half

- Diluted EPS ₹5.30 (~$0.055/ADR), down from ₹17.00

- EBITDA ₹1,009 cr, −56%; margin 12.5% (was 26.7%); 15.4% ex the one-time charge

- Gross margin 46.5% (49.4% ex-charge); total expenses +13.6% as sales fell

- North America −35% to ₹2,205 cr (lenalidomide/gRevlimid window closed Jan 2026)

- Base business double-digit: Emerging Mkts +31%, India +17%, Europe +13%, PSAI +4%

- One-time ₹240 cr semaglutide API write-off; supply back ~late Oct/early Nov

- Net cash surplus ₹3,058 cr (~$317M) at Jun 30; R&D ~7% of sales; FY26 dividend ₹8/sh

- FY27 guidance reaffirmed (sales + profit); ADR 1:1; FX ~₹96.4/USD; ~834M shares

- Our owner-earnings DCF fair value ~$10 vs ~$11.40 — HOLD 3/5, no margin of safety

- Street lean Buy (6B/4H/2S), ~$14.5 ADR target — but predates the miss; likely trimmed

What to watch: evidence the refill is replacing the lost U.S. windfall — the semaglutide relaunch landing on schedule (late Oct/early Nov), biosimilar approvals like abatacept, and India + emerging-market growth holding double-digits into a cleaner FY28 — would justify an upgrade; the risks to respect are U.S. price erosion outrunning the base, another quality stumble, or the pipeline slipping, so watch the base-business growth rate and the semaglutide restart every quarter

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Otis Worldwide (OTIS) Q2 2026 — Otis Worldwide (OTIS), the world's largest elevator & escalator company and the biggest recurring maintenance-service annuity on Earth (~2.5M units under contract, moving 2.5B people a day), reported Q2 2026: revenue rose 7% to $3.86B (organic +6%, a beat), and GAAP EPS jumped 13% to $1.12 — but that was flattered by the absence of prior-year separation costs; the clean, comparable adjusted EPS actually FELL 4% to $1.01 (merely in line), and adjusted operating profit declined $25M. The bright spot was the Service annuity: organic sales +9% (its best since the 2020 spin), modernization organic +24% with backlog +24%. The catch: management CUT full-year adjusted EPS guidance ~4.5% to ~$4.03, adjusted operating margin compressed 180 bps, and China New Equipment fell high-teens (Asia-Pacific orders down 20%+). The stock slid ~2% to ~$70, sitting on its 52-week low (~$69) and ~26% below its $95 high. At ~17.5x earnings with a 2.5% dividend (raised 5% to $0.44/qtr) it looks cheap — but our owner-earnings DCF, subtracting ~$7.6B of spin-off net debt, lands fair value near $72, essentially on top of the price. Our call: HOLD, 3/5 — a world-class annuity, but the drawdown is largely deserved and there's no margin of safety yet.

Otis Worldwide is one of the highest-quality industrials on the planet — a razor-and-blades machine that sells elevators near break-even, then services them for decades at a ~23% margin. It runs the world's largest maintenance portfolio (~2.5M units) and moves 2.5 billion people a day. Yet the stock just hit a 52-week low near $70, down ~26% from its $95 high, and it fell again on this print. Why? Q2 2026 was a split decision: revenue beat (+7% to $3.86B, organic +6%) and GAAP EPS rose 13% to $1.12 — but that headline is flattered by the absence of prior-year separation costs; the clean adjusted EPS FELL 4% to $1.01 and adjusted operating profit actually declined $25M. The Service annuity is genuinely excellent — organic sales +9% (best since the 2020 spin), modernization organic +24%, backlog +24% — but it's masked by three real problems: management CUT full-year adjusted EPS guidance ~4.5% to ~$4.03, adjusted margin compressed 180 bps on heavy reinvestment and material costs, and China New Equipment is falling off a cliff (high-teens decline, Asia-Pac orders down 20%+). The honest read: adjusted profit and free cash flow are actually DECLINING this year, so the de-rating isn't irrational. On our owner-earnings DCF — base FCF ~$1.5B, modeled on a mid-cycle (+6%) vs Service-compounder (+8.5%) path, discounted at 8–10% and net of ~$7.6B debt — fair value lands near $72, right on top of the ~$70 price. Our call: HOLD, 3/5. We're not sellers of an annuity this good, but at these levels there's no margin of safety and the drawdown was earned. Interestingly, Wall Street is ALSO at Hold — but with ~$92 targets implying 30%+ upside (already coming down: Barclays just cut to $90, Underweight). We agree on the rating, disagree on value: we think it's roughly fairly valued, not cheap. Add on genuine weakness below $65, own it for the quality, and don't mistake a big drawdown for a big bargain. Not financial advice.

THE CALL: HOLD (3/5, A WORLD-CLASS SERVICE ANNUITY, FAIRLY VALUED AFTER A DESERVED RESET — CHEAP ON THE SURFACE, NO MARGIN OF SAFETY UNDERNEATH) — base-case value ~$72 vs ~$70 today.

What to watch: evidence the reset is ending — adjusted operating margins re-expanding, China New Equipment stabilizing, and modernization organic growth holding in the low-20s — which would validate the Service-compounder path and prompt an upgrade; the risks to respect are Service growth fading, further margin compression, another guidance cut, or a deeper China property downturn that, because every un-installed elevator is a lost future maintenance contract, quietly starves the Service annuity a decade out

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Moody's Corporation (MCO) Q2 2026 — Moody's Corporation (MCO), half of the global credit-ratings duopoly, reported a strong Q2 2026: revenue rose 15.1% YoY to $2.19B (beating by ~4.8%) and adjusted diluted EPS of $4.68 topped the ~$4.26 estimate (+31% YoY, ~10% beat). GAAP EPS was $5.03 (+57%) but is flattered by a one-time gain on a divested business — the cleaner number is the $4.68 adjusted. The engine of the beat was ratings: Moody's Investors Service (MIS) revenue jumped ~25% to a record ~$1.2B at a 67% adjusted margin, with data-center/AI-infrastructure debt driving the public/project/infrastructure-finance line +38% on $2T+ of rated issuance. Moody's Analytics (MA) grew a steadier 4% (8% organic cc, 99% recurring, ARR +8%). Yet the stock went nowhere (~$493, ~flat): despite the beat, management only nudged the FLOOR of full-year adjusted-EPS guidance to $16.50–$17.00 (from $16.40), leaving the midpoint ~unchanged — it did NOT flow the beat through. At ~29x forward earnings and ~31x FCF, even our optimistic data-center-compounder DCF lands fair value near $475 — essentially on top of the price. Our call: HOLD.

Moody's is one of the highest-quality businesses in the market — half of an effective ratings duopoly with S&P Global (a toll booth almost every bond issuer must pay, at a stunning 67% margin) bolted onto Moody's Analytics, a 99%-recurring subscription data-and-software arm. Q2 2026 was a genuinely strong quarter: revenue +15.1% to $2.19B (beat ~4.8%), adjusted diluted EPS of $4.68 vs the ~$4.26 estimate (+31% YoY). The engine of the beat was the AI-capex boom showing up directly in the P&L: MIS ratings revenue surged ~25% to a record ~$1.2B as companies rushed to borrow, with data-center and AI-infrastructure financing pushing the public/project/infrastructure-finance line +38% on $2T+ of rated issuance. MA compounded a steadier 4% (8% organic cc, ARR +8%). Two honest catches, though. First, the flashy $5.03 GAAP EPS (+57%) is inflated by a one-time gain on a business Moody's divested this quarter — anchor on the $4.68 adjusted. Second, and more telling: despite the beat, management only raised the FLOOR of full-year adjusted-EPS guidance ($16.40→$16.50, midpoint ~$16.75 ~unchanged) — it did not flow the beat through, a quiet signal that it sees part of this issuance surge as cyclical, not structural. That's why a strong headline produced a flat stock (~$493, ~10% off its $547 high). The business is asset-light and gushes cash (first-half FCF +34% to $1.53B; FY26 FCF guide $2.7–$2.9B; buybacks up to $3.0B; ROIC ~24%). So the debate isn't quality — it's price. At ~29x forward earnings and ~31x FCF, even giving Moody's the optimistic data-center-compounder path (12%→8% FCF growth) AND a premium, quality discount rate, our owner-earnings DCF lands fair value near $475 — right on top of today's $493; a mid-cycle path is worth less. A wonderful company with no margin of safety. Our call: HOLD, 3/5. We're a notch more cautious than the Street's bullish ~$539 target (Buy, 18 of 32 analysts). Own it for the quality, add on real weakness in the low $400s, and watch issuance volumes. Not financial advice.

THE CALL: HOLD (3/5, A WIDE-MOAT COMPOUNDER, PRICED FOR PERFECTION — A REAL AI-DEBT TAILWIND WITH NO MARGIN OF SAFETY) — base-case value ~$475 vs ~$493 today.

What to watch: evidence the issuance surge is STRUCTURAL rather than cyclical — several quarters of durable data-center and AI-infrastructure financing plus accelerating Moody's Analytics recurring revenue — which would justify the premium multiple and prompt an upgrade; the risk to respect is a credit freeze, a rate spike, or an AI-capex pause that stalls debt issuance, which at ~29x earnings and ~31x FCF could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Equinor (EQNR) Q2 2026 — Equinor ASA (EQNR), Norway's state-controlled integrated oil & gas major, reported a strong Q2 2026. Net operating income more than DOUBLED YoY to $12.99B (from $5.72B), adjusted operating income was $11.48B pre-tax, and adjusted net income was $3.22B — $1.33/share — on a high-price quarter (European gas $15.8/mmbtu, liquids $97.9/bbl). Production grew 3% to 2.165M boe/day as new fields (Eirin, Symra) came online, and cash flow from operations after tax was $7.68B on $3.35B organic capex. The balance sheet is a fortress: net-debt-to-capital fell to 10.4% (from 15.3%). Capital return is the headline — a ~4% ordinary dividend ($0.39/qtr) PLUS a buyback raised to up to $3B for 2026 (third tranche up to $1,125M) = a total shareholder yield ~7%, among the highest of the majors — and EQNR trades ~3x EV/EBITDA, the CHEAPEST major. But three catches keep it a HOLD: it's 67% Norwegian-STATE-owned (buybacks even include State redemption), earnings are levered to volatile European gas (this was a peak-price quarter), and the renewables/transition build-out is a capital drag (a ~$1.6B FY2025 loss incl. an Empire Wind write-down), plus a ~78% home petroleum tax. The stock has already nearly DOUBLED off its ~$22 low (Dec 2025) to ~$39, near its 52-week high of $43.46. On a mid-cycle FCF DCF (net of debt), our probability-weighted fair value is ~$40 — right at the ~$39 price. Our call: HOLD, 3/5 — ALIGNED with the Street's Hold / ~$38 target.

Equinor is Norway's state-controlled energy champion and one of the world's lowest-cost integrated oil & gas majors — anchored on the Norwegian continental shelf (giant fields like Johan Sverdrup), pumping ~2.2M boe/day, running one of Europe's largest gas-trading arms, and building out renewables. Q2 2026 was a genuinely strong, high-price quarter: net operating income more than DOUBLED YoY to $12.99B (from $5.72B), adjusted operating income was $11.48B pre-tax ($3.44B after Norway's heavy petroleum tax), and adjusted net income was $3.22B, or $1.33/share, on a realized European gas price of $15.8/mmbtu and $97.9/bbl liquids. Production rose 3% to 2.165M boe/day. Cash flow from operations after tax was $7.68B — but note the tax bite: Equinor paid $6.4B of NCS petroleum taxes in the quarter, so nearly half its ~$14.75B pre-tax operating cash went to Oslo before shareholders saw a cent. The draw is capital return: a ~4% ordinary dividend PLUS a buyback raised to up to $3B for 2026 = a ~7% total shareholder yield, among the fattest of the majors, funded by ~$35/bbl NCS break-evens and a fortress balance sheet (net-debt-to-capital just 10.4%, down from 15.3%). On EV/EBITDA, EQNR is the CHEAPEST major at ~3x (vs 4–5x Shell/BP/Total, 10x+ Exxon). So why only a HOLD? Three catches. (1) State control — the Norwegian State owns 67%, so strategy and payout serve Oslo first (the buyback even includes shares redeemed from the State). (2) Gas-price beta — earnings swing hard with European gas, and this was a peak-price quarter; strip prices to mid-cycle and the cheap multiple isn't so cheap (FCF yield is only ~2% after heavy capex). (3) The transition drag — renewables lost ~$1.6B in FY2025 (incl. an Empire Wind write-down), pouring capital in at uncertain returns. Valuing a cyclical on MID-CYCLE (not peak) free cash flow — normalized FCF to shareholders of ~$7–9B/yr, discounted at 8/9/10% and net of ~$13B net debt — our two-scenario DCF spans ~$35–$49 (mid-cycle, ~$10–11 gas / ~$72 Brent) and ~$47–$66 (up-cycle, gas stays tight / ~$90 Brent), with a genuine ~$26 soft-gas downside. Probability-weighted (45% mid / 25% up / 30% soft-gas), fair value is ~$40 — right at the ~$39 price, after the stock already nearly DOUBLED off its ~$22 December low into strong commodity prices and now sits near its 52-week high. That's no margin of safety, though the ~7% yield pays you to wait. Notably, Wall Street is also a Hold (~7 buy / 13 hold / 3 sell) with a ~$38 average target — essentially at today's price — so our model and the Street land in the same place. Our verdict: HOLD, 3/5 — a cheap, high-yield, well-run major, but one capped by its state owner, its gas-price beta, and a costly transition, trading right at fair value. A company to respect and a price to wait on. Not financial advice.

THE CALL: HOLD (3/5, A CHEAP, CASH-GUSHING MAJOR WITH A FORTRESS BALANCE SHEET AND A ~7% SHAREHOLDER YIELD — BUT 67% STATE-CONTROLLED, LEVERED TO VOLATILE EUROPEAN GAS AT A PEAK-PRICE QUARTER, AND DRAGGED BY A LOSS-MAKING TRANSITION BUILD-OUT — TRADING RIGHT AT MID-CYCLE FAIR VALUE AFTER A NEAR-DOUBLE OFF ITS LOWS, WITH NO MARGIN OF SAFETY) — base-case value ~$40 vs ~$39 today.

What to watch: Watch European gas (the realized price was $15.8/mmbtu this quarter) above all else — it is the single biggest driver of Equinor's cash flow and value, and this was a peak-price quarter that won't repeat at mid-cycle. We'd turn more constructive on a pullback toward ~$32 or below (closer to the soft-gas case, where the ~7% yield pays you to wait and the discount widens), or on durable evidence European gas is structurally higher-for-longer AND the renewables build-out starts earning its cost of capital instead of draining it (the up-cycle re-rate). The risk to respect is the opposite: gas rolling over toward ~$8/mmbtu on a mild winter or oversupply, which would shrink the free-cash-flow thesis and expose how much of this quarter was just price. Secondary watch items: the 67% Norwegian-State owner's stance on dividends and buybacks, and net-debt-to-capital (10.4%, improving).

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

AT&T (T) Q2 2026 — AT&T beat on Q2 (adjusted EPS $0.65 vs ~$0.59), added a record 646K internet subscribers (367K fiber + 279K fixed wireless) and 432K postpaid phone lines, grew free cash flow to $4.7B, and accelerated buybacks toward ~$10B — the stock popped ~5% but is still ~30% off its 12-month high near $30.

AT&T (T) — a ~$162B connectivity utility — slid ~30% to a low near $20.50 before this strong Q2 print bounced it back to ~$23. At ~6x EV/EBITDA and an ~11% free-cash-flow yield, with a covered ~4.8% dividend and accelerating buybacks, the investment-led fiber-and-wireless strategy is visibly working. But it is still a ~2%-growth telecom carrying $126B of net debt.

THE CALL: BUY (3/5, CHEAP CASH FLOW, HEAVY DEBT) — base-case value ~$30 vs ~$23 today.

KEY METRICS:

- Q2 2026: revenue $31.6B (+2.3% YoY); adjusted EPS $0.65 (beat ~$0.59), GAAP EPS $0.66 (up from $0.62); adjusted EBITDA $12.3B (+5.2%)

- Free cash flow $4.7B in Q2; FY2026 guide $18B+ (rising to $21B+ by 2028) — an ~11% FCF yield at ~$23

- Record 646K internet net adds (367K fiber + 279K fixed wireless); 432K postpaid phone adds, churn just 0.86%

- Fiber passes 38.6M locations, on track for 40M+ by end-2026 and 60M+ by 2030; 42.5% convergence (home internet + wireless)

- Dividend $1.11/yr (~4.8%, only ~43% of FCF); accelerating buybacks to ~$10B in 2026; $45B+ total capital return 2026-2028

- Net debt $126.4B (~2.6x adjusted EBITDA, targeting the 2.5x range); all FY2026-2028 guidance reiterated (adj EPS $2.25-$2.35 in 2026)

- Peers: AT&T ~6x EV/EBITDA vs Verizon ~7.7x, T-Mobile ~11.6x; AT&T has the highest FCF yield (~11%) and, on a like-for-like basis, the lowest leverage

- Owner-earnings / free-cash-flow DCF (discount 9-11%, base 10%; net of the $126B debt): base ~$30, bull ~$37, bear ~$24 (≈ price); prob-weighted ~$30 vs ~$23

- Wall Street: Moderate Buy, average target ~$29-30 (range $18-$36) — our BUY (3/5) is aligned, at the constructive end

What to watch: free cash flow holding above $18B and net debt falling toward the 2.5x target — plus continued fiber and postpaid growth; the risks are capex creep, an adds stall, or costlier refinancing on the debt

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Philip Morris International (PM) Q2 2026 — Philip Morris International (PM) reported Q2 2026 results that look contradictory at the headline but are strong underneath. Reported GAAP diluted EPS FELL 7.7% YoY to $1.80 — but that entire drop is a $511M non-cash impairment of its deconsolidated Canadian affiliate (RBH), worth 33c/share. On the measure management runs the business, ADJUSTED diluted EPS jumped 15.2% to $2.20 (+13.6% ex-currency), beating the ~$2.04 estimate. Net revenues topped $11.2B for the first time ever (+10.4% reported, +7.6% organic), operating income rose 22%, and the smoke-free business (IQOS + ZYN + VEEV) grew ~12% to ~42% of revenue, now in 109 markets. Combustibles still grew ~10% on 10% pricing — remarkable power for a declining-volume product. PM RAISED its FY2026 adjusted-EPS outlook to $8.26–$8.41 (+9.5% to +11.5%), though only for currency (favorable FX trimmed from $0.20 to $0.15). The catch: the stock (~$188) sits just below its all-time high near $195, trades at ~23x adjusted earnings with only a ~3% yield (a premium-staples multiple), carries ~$44B of net debt after Swedish Match (buybacks suspended to deleverage), and earns 100% of revenue outside the U.S. (constant FX risk). On an owner-earnings / FCF DCF net of ~$44B net debt (7/8/9% discount, base ~$13.5B FCF), our probability-weighted fair value is ~$170 — a bit BELOW the ~$188 price. Our call: HOLD, 3/5 — a great business at a full price, modestly more cautious than the Street's Buy / ~$200 average target (which itself is only ~6% above the price).

Philip Morris International is no longer just a cigarette company — it's a smoke-free champion. It sells Marlboro and other cigarettes everywhere outside the U.S. (a mature, pricing-powered cash cow), but the real story is the pivot to smoke-free: it owns IQOS (the leading heat-not-burn device, ~three-quarters of its global category), ZYN (the US nicotine-pouch phenomenon), and VEEV (e-vapor). Smoke-free products are now sold in 109 markets, used by 43M+ people, and account for ~42% of revenue. Q2 2026 looked contradictory at the headline: reported GAAP diluted EPS FELL 7.7% to $1.80 — but that entire decline is a $511M non-cash impairment of the deconsolidated Canadian affiliate (RBH), worth 33c/share, and says nothing about how IQOS or ZYN are selling. On the adjusted basis management runs the business by, EPS jumped 15.2% to $2.20 (+13.6% ex-currency), beating the ~$2.04 estimate. Net revenues topped $11.2B for the first time (+10.4% reported, +7.6% organic), operating income rose 22%, gross margin expanded, and the smoke-free business grew ~12%. The bull case is genuine: IQOS volumes +8% holding ~75% category share, ZYN with fresh first-ever FDA MRTP authorization for 20 variants (~2.9B pouches), and combustibles taking +10% price — proving Marlboro funds the whole transition. Management RAISED FY2026 adjusted-EPS guidance to $8.26–$8.41 (currency only). So why only a HOLD? Because the quality is not a secret and the price already reflects it. PM trades at ~23x adjusted earnings and ~18x cash flow with only a ~3% yield — a premium-staples multiple, closer to Coca-Cola (~26x) than to tobacco peers Altria (~15x) or BTI (~13x), which yield 5%+. It sits just below its all-time high, carries ~$44B of net debt after the Swedish Match deal (buybacks suspended to deleverage toward ~2x by year-end), and earns 100% of revenue outside the U.S., so a strong dollar is a constant headwind — exactly why guidance moved this quarter. Valuing a stable, pricing-powered compounder on owner earnings — normalized FCF of ~$13.5B/yr, discounted at 7/8/9% and net of ~$44B net debt — our two-scenario DCF spans ~$140–$210 (base, smoke-free offsets combustible decline, +5% FCF growth) and ~$175–$280 (bull, IQOS+ZYN compound, +7%), with a genuine ~$120 downside if combustibles fade faster or the dollar stays strong. Probability-weighted (50% base $170 / 25% bull $215 / 25% bear $120), fair value is ~$170 — a touch below the ~$188 price. That's no margin of safety for new money. Notably, even the Street's Buy rating carries an average target of only ~$200 — just ~6% above the price — so even the bulls see limited upside. Our verdict: HOLD, 3/5 — a world-class, smoke-free compounder and a genuinely strong quarter, but fully priced near its all-time high. A company to admire, and a price to wait on. Not financial advice.

THE CALL: HOLD (3/5, A WORLD-CLASS, PRICING-POWERED SMOKE-FREE COMPOUNDER (IQOS + ZYN) THAT JUST POSTED A STRONG QUARTER THE GAAP HEADLINE HIDES — BUT TRADES AT A PREMIUM-STAPLES MULTIPLE NEAR ITS ALL-TIME HIGH, WITH ~$44B NET DEBT AND 100% FX EXPOSURE, LEAVING NO MARGIN OF SAFETY AT ~$188 VS OUR ~$170 FAIR VALUE) — base-case value ~$170 vs ~$188 today.

What to watch: Watch the smoke-free growth rate (IQOS volumes + ZYN) and the debt trajectory above all else — those two numbers decide whether the premium is earned. We'd turn more constructive on a pullback toward ~$160 or below (where the dividend yield rises toward 4% and a real margin of safety opens up), or on continued double-digit smoke-free growth PLUS visible debt paydown toward the ~2x leverage target (which would resume buybacks and justify a higher value — the path toward the bull case). The risks to respect: an accelerating decline in cigarette volumes, a sustained strong dollar squeezing reported guidance (PM earns 100% ex-US), or a regulatory shock on IQOS or ZYN (excise-tax hikes like Japan, flavor bans like Poland) — any of which pulls value toward the ~$120 bear case. At ~$188 vs our ~$170 prob-weighted fair value, there's no margin of safety, which is why we wait rather than chase.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Wabtec (Westinghouse Air Brake Technologies) (WAB) Q2 2026 — Wabtec (WAB), the 155-year-old rail-equipment leader, reported a strong Q2 2026: adjusted EPS of $2.76 beat and rose 21.6% YoY (GAAP EPS $2.33) on net sales of $3.18B (+17.5%), with adjusted operating margin up 0.8 pts to 21.9%. Both segments grew — Freight $2.24B (+16.9%, 25.8% margin) and Transit $936M (+18.9%, 17.7% margin) — and management RAISED full-year guidance to adjusted EPS $10.60–$10.90 and revenue $12.3–$12.6B. Operating cash flow more than doubled to $441M (82% conversion), $215M of stock was repurchased, and the multi-year backlog reached $30.9B. The catch: the beat leaned on cyclical new-build locomotives (equipment +35%) while high-margin services fell 4.2%, and at ~24–25x earnings near a record high, our owner-earnings DCF lands near $245 — below the ~$263 price and the Street's ~$300 target. Our call: HOLD.

Wabtec is one of the industrial world's quiet compounders — the 155-year-old, ~$44B rail-equipment leader that builds the locomotives, brakes, components, digital controls and aftermarket services that keep global freight and passenger trains moving. Q2 2026 was a clean beat-and-raise: adjusted EPS of $2.76 beat and rose 21.6% YoY (GAAP $2.33, +18.9%) on net sales of $3.18B (+17.5%), adjusted operating margin expanded to 21.9%, and — for another quarter running — management RAISED full-year guidance (adj EPS $10.60–$10.90, revenue $12.3–$12.6B). Both segments grew double digits: Freight $2.24B (+16.9%) at a rich 25.8% adjusted operating margin, Transit $936M (+18.9%) at 17.7%. Operating cash flow more than doubled to $441M at 82% conversion, funding $215M of buybacks and a $53M dividend, and the multi-year backlog hit $30.9B. Here's the honest twist, though: the beat leaned on cyclical new-build locomotives (Freight equipment +35%) while the vaunted high-margin services annuity actually fell 4.2%, and the +88.5% digital jump was mostly acquisitions. The headline $30.9B backlog (+41.7%) is flattered by FX and M&A; the cleaner 12-month backlog grew a solid-but-normal 11.3%. It's a wonderful franchise — but the stock has re-rated ~50% off its 2025 low to ~$263, about 24–25x earnings and ~26x free cash flow, near a record high. Even giving Wabtec an aggressive +9% owner-earnings path, our DCF fair value blends to ~$245 — below today's price, and the optimistic case only reaches ~$280. A great company with no margin of safety. Our call: HOLD, 3/5. We're not sellers of quality this good, but near record highs we wouldn't chase it — and we're notably more cautious than the Street's ~$300 target (Moderate Buy). Own it for the quality, add on real weakness toward $225, and watch orders and book-to-bill. Not financial advice.

THE CALL: HOLD (3/5, A GREAT RAIL COMPOUNDER, PRICED FOR IT — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$245 vs ~$263 today.

KEY METRICS:

- Q2 net sales $3.18B, +17.5% YoY (8-K/press release, 7/22/26)

- Adjusted diluted EPS $2.76, +21.6% YoY; GAAP EPS $2.33, +18.9% (8-K)

- Adjusted operating margin 21.9%, +0.8 pts; adj gross margin 36.7% (8-K)

- Freight $2,243M (+16.9%, 25.8% adj op margin); Transit $936M (+18.9%, 17.7%) (8-K)

- FY2026 guidance RAISED: adjusted EPS $10.60–$10.90, revenue $12.3–$12.6B (8-K)

- Multi-year backlog $30.9B (+41.7%); cleaner 12-month backlog $9.1B (+11.3%) (8-K)

- Operating cash flow $441M (82% conversion); $215M buybacks + $53M dividend (8-K)

- Our owner-earnings DCF fair value ~$245 vs $263 price; Street ~$300, Moderate Buy

What to watch: hard evidence the high-margin services and aftermarket annuity is reaccelerating alongside sustained locomotive orders — proving the growth is durable rather than a cyclical, equipment- and acquisition-led bounce — which would justify the premium multiple and prompt an upgrade; the risk to respect is a pause in railroad capital spending or order cancellations, which at ~24–25x earnings near record highs could re-rate the stock quickly

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

GE Vernova (GEV) Q2 2026 — GE Vernova (GEV), the power-and-grid company spun out of the old General Electric, reported a blockbuster Q2 2026: orders exploded +88% organically to $24.2B, revenue rose 22% to $11.1B (+12% organic), adjusted EBITDA jumped to $1.25B (an 11.3% margin, +340bps organic), and free cash flow hit $5.1B — more than all of 2025. Management RAISED full-year guidance, nearly DOUBLING the free-cash-flow outlook to $11.5–12.5B and lifting revenue to $45.5–46.5B, on a $176B backlog. GAAP EPS was $2.47 (+33% YoY), a touch light versus the Street's number. The stock (~$1,079, flat on the print) has roughly doubled off its $530 low and sits ~10% below its $1,196 high. The catch: at ~48x adjusted EBITDA, even our optimistic supercycle DCF lands fair value near $800 — below the price — because much of that free cash flow is customer advance payments that normalize. Our call: HOLD, 3/5.

GE Vernova is the market's purest play on the electricity supercycle — the energy business carved out of the old General Electric in 2024, selling exactly what AI data centers, reshoring, and electrification suddenly can't get enough of: gas turbines and grid equipment. Q2 2026 was a blowout on the metrics that matter: orders exploded +88% organically to $24.2B, revenue rose 22% to $11.1B (+12% organic), adjusted EBITDA jumped to $1.25B (an 11.3% margin, up 340bps organically), and free cash flow surged to $5.1B — more than all of 2025. Power orders rose +134% (gas equipment under contract went from 100 to 116 GW, targeting 125+ by year-end); Electrification revenue grew +68% with a ~1.7 book-to-bill; only Wind lagged (revenue −10%, losses widening). Management RAISED guidance again — nearly DOUBLING the FCF outlook to $11.5–12.5B and lifting revenue to $45.5–46.5B — on a $176B backlog. GAAP EPS was $2.47 (+33% YoY), a touch light vs the Street. So the debate isn't quality — it's price. The stock has roughly doubled off its $530 low to ~$1,079, ~48x adjusted EBITDA. Here's the honest nuance: a big slice of that gorgeous free cash flow is customer down-payments on the booming gas backlog — advance payments that flatter cash today and normalize as turbines ship. Strip them out and anchor on normalized owner earnings (~$4.5B), and even our optimistic supercycle DCF lands fair value near $800 — below today's price; even the supercycle path at a 9% discount rate is only ~$1,025, still under the stock. A wonderful business with no margin of safety. Our call: HOLD, 3/5. We're not sellers of a compounder this good, but at these levels we wouldn't chase it — and we're more cautious than the Street's bullish ~$1,160 target (Buy, 21 of 28 analysts, 0 sells). Own it for the quality, add on real weakness toward $800, and watch margins and cash conversion. Not financial advice.

THE CALL: HOLD (3/5, A SUPERCYCLE WINNER, PRICED BEYOND PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$800 vs ~$1079 today.

What to watch: durable margin expansion plus free cash flow that holds up as gas-turbine advance payments normalize — and Wind finally turning profitable — which would prove the cash generation is structural, not just working-capital timing, and justify the premium multiple, prompting an upgrade; the risk to respect is a stall in orders, a crack in the AI-data-center power narrative, or a margin disappointment, which at ~48x adjusted EBITDA could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.